172 related articles for article (PubMed ID: 33493425)
1. Treatment Initiation in Patients with Interstitial Lung Disease in Canada.
Assayag D; Garlick K; Johannson KA; Fell CD; Kolb M; Cox G; Hambly N; Manganas H; Morisset J; Fisher JH; Shapera S; Gershon AS; To T; Sadatsafavi M; Wilcox PG; Halayko AJ; Khalil N; Ryerson CJ
Ann Am Thorac Soc; 2021 Oct; 18(10):1661-1668. PubMed ID: 33493425
[No Abstract] [Full Text] [Related]
2. Impact of Concomitant Medication Burden on Tolerability of Disease-targeted Therapy and Survival in Interstitial Lung Disease.
Khor YH; Goh NSL; Wong AW; Johannson KA; Marcoux V; Fisher JH; Assayag D; Manganas H; Khalil N; Kolb M; Ryerson CJ;
Ann Am Thorac Soc; 2022 Jun; 19(6):962-970. PubMed ID: 35007498
[No Abstract] [Full Text] [Related]
3. Sex- and Race-Based Differences in the Treatment of Interstitial Lung Diseases in North America and Australasia.
Assayag D; Adegunsoye A; Sheehy R; Morisset J; Khalil N; Johannson KA; Marcoux V; Kolb M; Fisher JH; Manganas H; Wrobel J; Wilsher M; De Boer S; Mackintosh J; Chambers DC; Glaspole I; Keir GJ; Lee CT; Jablonski R; Vij R; Strek ME; Corte TJ; Ryerson CJ
Chest; 2023 May; 163(5):1156-1165. PubMed ID: 36621759
[TBL] [Abstract][Full Text] [Related]
4. Baseline characteristics and comorbidities in the CAnadian REgistry for Pulmonary Fibrosis.
Fisher JH; Kolb M; Algamdi M; Morisset J; Johannson KA; Shapera S; Wilcox P; To T; Sadatsafavi M; Manganas H; Khalil N; Hambly N; Halayko AJ; Gershon AS; Fell CD; Cox G; Ryerson CJ
BMC Pulm Med; 2019 Nov; 19(1):223. PubMed ID: 31771541
[TBL] [Abstract][Full Text] [Related]
5. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
Lamb YN
Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
[TBL] [Abstract][Full Text] [Related]
6. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
Feng H; Zhao Y; Li Z; Kang J
Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
[TBL] [Abstract][Full Text] [Related]
7. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
[TBL] [Abstract][Full Text] [Related]
8. Disease Behaviour During the Peri-Diagnostic Period in Patients with Suspected Interstitial Lung Disease: The STARLINER Study.
Wijsenbeek MS; Bendstrup E; Valenzuela C; Henry MT; Moor CC; Jouneau S; Fois AG; Moran-Mendoza O; Anees S; Mirt M; Bengus M; Gilberg F; Kirchgaessler KU; Vancheri C
Adv Ther; 2021 Jul; 38(7):4040-4056. PubMed ID: 34117601
[TBL] [Abstract][Full Text] [Related]
9. A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease.
Wong AW; Lee TY; Johannson KA; Assayag D; Morisset J; Fell CD; Fisher JH; Shapera S; Gershon AS; Cox G; Halayko AJ; Hambly N; Manganas H; Sadatsafavi M; Wilcox PG; To T; Marcoux V; Khalil N; Kolb M; Ryerson CJ
Respir Res; 2020 Dec; 21(1):322. PubMed ID: 33287805
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and prognosis of unclassifiable interstitial lung disease.
Ryerson CJ; Urbania TH; Richeldi L; Mooney JJ; Lee JS; Jones KD; Elicker BM; Koth LL; King TE; Wolters PJ; Collard HR
Eur Respir J; 2013 Sep; 42(3):750-7. PubMed ID: 23222877
[TBL] [Abstract][Full Text] [Related]
11. Inhalational exposures in patients with fibrotic interstitial lung disease: Presentation, pulmonary function and survival in the Canadian Registry for Pulmonary Fibrosis.
Lee CT; Strek ME; Adegunsoye A; Wong AW; Assayag D; Cox G; Fell CD; Fisher JH; Gershon AS; Halayko AJ; Hambly N; Khalil N; Kolb M; Lok SD; Manganas H; Marcoux V; Morisset J; Sadatsafavi M; Shapera S; To T; Wilcox P; Ryerson CJ; Johannson KA
Respirology; 2022 Aug; 27(8):635-644. PubMed ID: 35512793
[TBL] [Abstract][Full Text] [Related]
12. Review series: Aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ?
de Lauretis A; Veeraraghavan S; Renzoni E
Chron Respir Dis; 2011; 8(1):53-82. PubMed ID: 21339375
[TBL] [Abstract][Full Text] [Related]
13. Understanding the determinants of health-related quality of life in rheumatoid arthritis-associated interstitial lung disease.
Natalini JG; Swigris JJ; Morisset J; Elicker BM; Jones KD; Fischer A; Collard HR; Lee JS
Respir Med; 2017 Jun; 127():1-6. PubMed ID: 28502413
[TBL] [Abstract][Full Text] [Related]
14. Idiopathic Interstitial Pneumonia Associated With Autoantibodies: A Large Case Series Followed Over 1 Year.
Collins BF; Spiekerman CF; Shaw MA; Ho LA; Hayes J; Spada CA; Stamato CM; Raghu G
Chest; 2017 Jul; 152(1):103-112. PubMed ID: 28300570
[TBL] [Abstract][Full Text] [Related]
15. A cohort study of Danish patients with interstitial lung diseases: burden, severity, treatment and survival.
Hyldgaard C
Dan Med J; 2015 Apr; 62(4):B5069. PubMed ID: 25872544
[TBL] [Abstract][Full Text] [Related]
16. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies.
Tanizawa K; Handa T; Nakashima R; Kubo T; Hosono Y; Watanabe K; Aihara K; Ikezoe K; Sokai A; Nakatsuka Y; Taguchi Y; Hatta K; Noma S; Kobashi Y; Yoshizawa A; Oga T; Hirai T; Chin K; Nagai S; Izumi T; Mimori T; Mishima M
Respir Med; 2017 Jun; 127():57-64. PubMed ID: 28461123
[TBL] [Abstract][Full Text] [Related]
17. Interstitial pneumonia with autoimmune features show better survival and less exacerbations compared to idiopathic pulmonary fibrosis.
Lim JU; Gil BM; Kang HS; Oh J; Kim YH; Kwon SS
BMC Pulm Med; 2019 Jul; 19(1):120. PubMed ID: 31272428
[TBL] [Abstract][Full Text] [Related]
18. Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease.
Gibson CD; Kugler MC; Deshwal H; Munger JS; Condos R
Lung; 2020 Aug; 198(4):597-608. PubMed ID: 32591895
[TBL] [Abstract][Full Text] [Related]
19. Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA.
Olson AL; Maher TM; Acciai V; Mounir B; Quaresma M; Zouad-Lejour L; Wells CD; De Loureiro L
Adv Ther; 2020 Jul; 37(7):3292-3298. PubMed ID: 32451950
[TBL] [Abstract][Full Text] [Related]
20. Cough is less common and less severe in systemic sclerosis-associated interstitial lung disease compared to other fibrotic interstitial lung diseases.
Cheng JZ; Wilcox PG; Glaspole I; Corte TJ; Murphy D; Hague CJ; Ryerson CJ
Respirology; 2017 Nov; 22(8):1592-1597. PubMed ID: 28544079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
